atenolol has been researched along with Cardiomyopathies in 8 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We also now have another bradycardic agent, ivabradine, which may prove very useful in heart failure patients who cannot tolerate a betablocker." | 4.84 | [What are the alternatives to betablockers in 2009?]. ( van de Borne, P, 2008) |
| " Chronic oral administration of nifedipine in combination with atenolol precipitated LV failure only in those with the lowest EF and highest LVEDP; usually LV failure was present with atenolol alone." | 2.66 | Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function. ( de Buitleir, M; Krikler, DM; Rowland, E, 1985) |
| "Flestolol is an ultrashort-acting beta-blocking drug with a half-life of 6." | 1.27 | Electropharmacology of flestolol for supraventricular tachycardia without associated structural heart disease. ( Blake, K; Franz, MR; Laddu, A; Liem, LB; Peterson, J; Swerdlow, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van de Borne, P | 1 |
| Fuentes, VL | 1 |
| Wolfson, R | 1 |
| Müller-Brunotte, R | 1 |
| Kahan, T | 1 |
| López, B | 1 |
| Edner, M | 1 |
| González, A | 1 |
| Díez, J | 1 |
| Malmqvist, K | 1 |
| Jacob, AS | 1 |
| Hafer, JG | 1 |
| Sakai, K | 1 |
| Abiko, Y | 1 |
| Swerdlow, C | 1 |
| Peterson, J | 1 |
| Liem, LB | 1 |
| Blake, K | 1 |
| Franz, MR | 1 |
| Laddu, A | 1 |
| de Buitleir, M | 1 |
| Rowland, E | 1 |
| Krikler, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy[NCT00389168] | Phase 2/Phase 3 | 115 participants (Actual) | Interventional | 1995-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Atenolol | -16.3 |
| Irbesartan | -18.8 |
Changes in common carotid artery intima-media thickness, assessed by ultrasonography. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | mm (Mean) |
|---|---|
| Atenolol | 0.03 |
| Irbesartan | -0.01 |
Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication. (NCT00389168)
Timeframe: Treatment period was baseline to 48 weeks
| Intervention | Participants (Number) |
|---|---|
| Atenolol | 5 |
| Irbesartan | 5 |
Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2). (NCT00389168)
Timeframe: Baseline and 48 weeks
| Intervention | g/m^2 (Mean) | ||
|---|---|---|---|
| 12 weeks | 24 weeks | 48 weeks | |
| Atenolol | -1 | -6 | -14 |
| Irbesartan | -9 | -14 | -26 |
Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | pmol/L (Mean) | ||
|---|---|---|---|
| Weel 12 | Week 24 | Week 48 | |
| Atenolol | -1.0 | -0.8 | -0.2 |
| Irbesartan | 3.0 | 3.3 | 10.0 |
Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points. (NCT00389168)
Timeframe: Baseline to 48 weeks
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| Week 12 | Week 24 | Week 48 | |
| Atenolol | 0.18 | 0.16 | 0.13 |
| Irbesartan | 0.10 | 0.04 | 0.10 |
2 reviews available for atenolol and Cardiomyopathies
| Article | Year |
|---|---|
[What are the alternatives to betablockers in 2009?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Cardiomyopathies; Heart Failur | 2008 |
Diastolic function--is this the key to successful management of many feline cardiomyopathies?
Topics: Animals; Atenolol; Cardiomyopathies; Cat Diseases; Cats; Congresses as Topic; Diastole; Diltiazem; E | 2003 |
2 trials available for atenolol and Cardiomyopathies
| Article | Year |
|---|---|
Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2007 |
Hemodynamic effects of nifedipine given alone and in combination with atenolol in patients with impaired left ventricular function.
Topics: Administration, Oral; Adult; Angiography; Atenolol; Blood Pressure; Cardiac Catheterization; Cardiom | 1985 |
4 other studies available for atenolol and Cardiomyopathies
| Article | Year |
|---|---|
Unclassified cardiomyopathy in a geriatric cat.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atenolol; Bradycardi | 2005 |
Selective (beta-1) blockade in congestive cardiomyopathy.
Topics: Atenolol; Cardiac Output; Cardiomyopathies; Humans; Male; Middle Aged; Propanolamines; Shock, Cardio | 1983 |
Attenuation by atenolol of myocardial acidosis during ischemia in dogs: contribution of beta-1 adrenoceptors to myocardial acidosis.
Topics: Acidosis; Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiomyopathies; Coronary | 1985 |
Electropharmacology of flestolol for supraventricular tachycardia without associated structural heart disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Cardiac Pacing, Artificial; Cardiomyopathies; El | 1987 |